Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis
Authors:
Open Access
- 1 November 2024
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 56 (1) , 2419993
Abstract
Not all patients benefit from transarterial chemoembolization (TACE) due to the heterogeneity of the tumour burden in intermediate-stage hepatocellular carcinoma (HCC). To compare the outcomes of transarterial chemoembolization (TACE) combined with molecular-targeted agents plus immune checkpoint inhibitors (TACE-MTAs-ICIs) with those of TACE for patients with unresectable hepatocellular carcinoma (uHCC) that were beyond the up-to-seven criteria. Between January 2019 and July 2022, 130 patients diagnosed with uHCC beyond the up-to-seven criteria were retrospectively identified, including 47 patients who received TACE-MTAs-ICIs and 83 patients who received TACE alone. The primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoints included tumour response and adverse events (AEs). There were 43 matched patients. The median OS and PFS times in the TACE-MTAs-ICIs group were significantly longer than those in the TACE group (OS: 27.2 vs. 15.9 months, p = 0.007; PFS: 15.4 months vs. 4.8 months, p < 0.001). The objective response rate (ORR) in the TACE-MTAs-ICIs group was higher than that in the TACE group (65.1% vs. 37.2%, p = 0.010). Reversible AEs (grade 3 or 4) occurred differently in TACE-MTAs-ICIs and TACE groups (83.7% vs. 51.2%, p = 0.001). Univariate and multivariate analyses revealed that TACE-MTAs-ICIs treatment was an independent favourable prognostic factor for both PFS and OS (p < 0.001). For uHCC patients beyond the up-to-seven criteria, TACE-MTAs-ICIs provided superior ORR and OS. Early combined TACE and systemic treatment should shift for patients who are beyond these criteria.Keywords
Funding Information
- Interventional Medicine Research Fund of Jiangsu Medical Association
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
This publication has 33 references indexed in Scilit:
- Molecular therapies and precision medicine for hepatocellular carcinomaNature Reviews Clinical Oncology, 2018
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challengesNature Reviews Clinical Oncology, 2018
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerationsJournal for ImmunoTherapy of Cancer, 2018
- Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2Digestive Diseases, 2017
- Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)Digestive Diseases, 2015
- Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinomaJournal of Hepatology, 2015
- How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinomaJournal of Hepatology, 2014
- Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment DecisionsSeminars in Liver Disease, 2012
- Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelinesJournal of Hepatology, 2012
- Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patientsCancer Science, 2008